Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, and CD4+ T cells form the core immunopathogenic cascade leading to chronic inflammation. Traditionally, Th1 cells (interferon-γ-producing CD4+ T cells) driven by interleukin 12 (IL12) were considered to be the encephalit...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2012/970789 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549857091387392 |
|---|---|
| author | Shyi-Jou Chen Yen-Ling Wang Hueng-Chuen Fan Wen-Tsung Lo Chih-Chien Wang Huey-Kang Sytwu |
| author_facet | Shyi-Jou Chen Yen-Ling Wang Hueng-Chuen Fan Wen-Tsung Lo Chih-Chien Wang Huey-Kang Sytwu |
| author_sort | Shyi-Jou Chen |
| collection | DOAJ |
| description | Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, and CD4+ T cells form the core immunopathogenic cascade leading to chronic inflammation. Traditionally, Th1 cells (interferon-γ-producing CD4+ T cells) driven by interleukin 12 (IL12) were considered to be the encephalitogenic T cells in MS and experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Currently, Th17 cells (Il17-producing CD4+ T cells) are considered to play a fundamental role in the immunopathogenesis of EAE. This paper highlights the growing evidence that Th17 cells play the core role in the complex adaptive immunity of EAE/MS and discusses the roles of the associated immune cells and cytokines. These constitute the modern immunological basis for the development of novel clinical and preclinical immunomodulatory therapies for MS discussed in this paper. |
| format | Article |
| id | doaj-art-62a8ded851944a2e92aecace57cc2d47 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-62a8ded851944a2e92aecace57cc2d472025-02-03T06:08:18ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/970789970789Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple SclerosisShyi-Jou Chen0Yen-Ling Wang1Hueng-Chuen Fan2Wen-Tsung Lo3Chih-Chien Wang4Huey-Kang Sytwu5Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, TaiwanCenter for Composite Tissue Allotransplantation, Chang Gung Memorial Hospital, Linkou, New Taipei City 333, TaiwanDepartment of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, TaiwanDepartment of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, TaiwanDepartment of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, TaiwanDepartment of Microbiology and Immunology, National Defense Medical Center, Taipei 114, TaiwanMultiple sclerosis (MS) is an autoimmune disease of the central nervous system, and CD4+ T cells form the core immunopathogenic cascade leading to chronic inflammation. Traditionally, Th1 cells (interferon-γ-producing CD4+ T cells) driven by interleukin 12 (IL12) were considered to be the encephalitogenic T cells in MS and experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Currently, Th17 cells (Il17-producing CD4+ T cells) are considered to play a fundamental role in the immunopathogenesis of EAE. This paper highlights the growing evidence that Th17 cells play the core role in the complex adaptive immunity of EAE/MS and discusses the roles of the associated immune cells and cytokines. These constitute the modern immunological basis for the development of novel clinical and preclinical immunomodulatory therapies for MS discussed in this paper.http://dx.doi.org/10.1155/2012/970789 |
| spellingShingle | Shyi-Jou Chen Yen-Ling Wang Hueng-Chuen Fan Wen-Tsung Lo Chih-Chien Wang Huey-Kang Sytwu Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple Sclerosis Clinical and Developmental Immunology |
| title | Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple Sclerosis |
| title_full | Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple Sclerosis |
| title_fullStr | Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple Sclerosis |
| title_full_unstemmed | Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple Sclerosis |
| title_short | Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple Sclerosis |
| title_sort | current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis |
| url | http://dx.doi.org/10.1155/2012/970789 |
| work_keys_str_mv | AT shyijouchen currentstatusoftheimmunomodulationandimmunomediatedtherapeuticstrategiesformultiplesclerosis AT yenlingwang currentstatusoftheimmunomodulationandimmunomediatedtherapeuticstrategiesformultiplesclerosis AT huengchuenfan currentstatusoftheimmunomodulationandimmunomediatedtherapeuticstrategiesformultiplesclerosis AT wentsunglo currentstatusoftheimmunomodulationandimmunomediatedtherapeuticstrategiesformultiplesclerosis AT chihchienwang currentstatusoftheimmunomodulationandimmunomediatedtherapeuticstrategiesformultiplesclerosis AT hueykangsytwu currentstatusoftheimmunomodulationandimmunomediatedtherapeuticstrategiesformultiplesclerosis |